Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476942 · ClinicalTrials.gov registry record
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 221
- Enrollment target
NCT02476942 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 221 participants.
The verdict
NCT02476942 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 221 participants
- Enrollment target
Study Summary
This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either episodic or prophylactic treatment). Actual patients will be enrolled from routine clinical practice in this observational study.
Interventions
- DRUG Bypassing Agents
- DRUG FVIII Replacement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-05-26 |
| Est. Completion | 2017-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476942
The ClinicalTrials.gov registry entry for NCT02476942 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bypassing Agents is the first listed.
NCT02476942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476942 about?
NCT02476942 is a clinical study titled "A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment". This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either ep...
What is the current status of trial NCT02476942?
This trial is currently completed. The enrollment target is 221 participants. The study started on 2015-05-26. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT02476942?
The interventions under investigation include: Bypassing Agents (DRUG), FVIII Replacement (DRUG).
Who is sponsoring clinical trial NCT02476942?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.